Semprus BioSciences Corp. won a $1 million grant to develop orthopedic devices resistant to biofilm formation for the U.S. Army’s Telemedicine & Advanced Technology Research Center.
Biofilms are the foundation for the most bacterial complications associated with implanted medical devices, according to a Semprus press release.
"Our goal is to dramatically reduce complication rates in orthopedic devices implanted in our men and women in the Armed Forces," CTO Christopher Loose said in prepared remarks. "We expect our technology to reduce wound complications, amputation and mortality in soldiers with orthopedic injuries."
Semprus develops technology to "coat" medical devices with its Sustain technology.
Instead of being "attached to [the device’s] surface in a temporary fashion," as CEO David Lucchino told MassDevice in a podcast interview earlier this year, Sustain is grown from the material itself as a "physical extension" of the device’s material.
"Think of it as billions of molecular-sized oak trees, and how you grow those oak trees out of the substrate … creates the long-term performance," Lucchino said.
The scope of the work done in collaboration with the army will focus on adapting Semprus technology to orthopedic materials, including titanium.
Here’s a roundup of other dealflow and investment news:
- EndoEvolution lands $3.3 million in Series B
EndoEvolution LLC, an device company developing next-generation automated suturing devices for minimally invasive surgery (MIS), raised $3.3 million in a Series B round, according to a press release.
- Humedica raises $23 million from 11 investors
Humedica Inc. closed a $23 million equity funding round comprised of 11 investors, according to SEC filings.
- SPR Therapeutics is halfway to $2 million funding goal
SPR Therapeutics raised $1 million of a hoped-for $2 million equity funding round with 6 investors thus far, according to SEC filings.
- C.R. Bard extends revolving credit up to $600 million
C.R. Bard (NYSE:BCR) extended its unsecured credit line to $600 million over a five-year period, according to SEC filings.
- ProUroCare renews $900,000 promissory note
ProUroCare Medical Inc. (OTC:PUMD), a pre-revenue company, renewed a $900,000 promissory note with Crown Bank, according to SEC filings.
- Opko scientist lands $4.2 million NIH grant
Opko Health Inc. (NYSE:OPK) scientist Thomas Kodadek landed $4.2 million from the National Institutes of Health to advance research in Type I diabetes, according to a press release.
- Chesson Labs raises $1.45 million of a hoped-for $2 million round
Chesson Labs Inc. inched closer to its $2 million goal for its latest funding round, having raised $1.45 million from 81 investors, according to SEC filings.